Rapid Therapeutic Science Laboratories (RTSL) is focused on providing our customers with the most therapeutic and effective solutions in the cannabis space. We were founded to find new ways to leverage cannabis in our daily lives and effective delivery systems for those of us who wish to consume cannabis.
We believe in the highest quality cannabis and manufacturing practices to ensure that you get the purest possible product that is produced to CPMG compliance. Our team has spent almost 50 years in the cannabis space, and we have seen the benefits that cannabis has for people of all backgrounds and conditions.
RTSL was founded on the basis of aerosol manufacturing and we have developed unique technology and formulations to meet the needs of our customers looking for line extensions to their typical tinctures, gummies, and oils. We have also expanded to three additional areas of cannabis and cannabis production. Consulting with companies on everything from seeds to extraction and beyond, product development, hemp acquisitions.
Please take a deeper look at each of these offerings and reach out to us if we can be of service to your company or customers.
Rapid Therapeutic Science Laboratories (RTSL) is committed to continuous research, development, and delivery of new products in the cannabis space.
With over 50 years of experience in the cannabis, pharmaceutical, consumer product and medical space, our team is uniquely positioned to help your business perform at the highest level possible.
Our goal is to help enhance your current strategy and product portfolio. We will meet with you to understand your business and needs and partner to ensure that we fill those to help you achieve peak performance.
Cannabis companies are rapidly developing, and we are here to help partner with you so that you don’t have to shoulder all of the load. Our consultants strive to ensure that anything that we bring to the table is actionable and tactically viable to deliver fast results to your business.
Rxoid is our flagship product at this moment and is a breakthrough cannabis device.
Rxoid delivers 4 main benefits for the consumer:
2. Safe, effective dosing
3. Quality ingredients (safest and best relief)
4. Fast acting
We believe you deserve natural, reliable and effective relief for what life throws at you.
We deliver the natural and effective relief you deserve in the exact dose you need.
The use of CBD is exploding across the US and the world and there are all kinds of stories and information about the therapeutic uses for it. We believe the key to safe and effective CBD use is to leverage the highest quality, natural CBD in the best delivery system. We have a wealth of experience in CBD, pharmaceutical and consumer goods and know that a quality delivery system can be the answer to providing effective relief. That is exactly what Rxoid has.
Our metered-dose inhaler delivers an accurate, effective and fast-acting dose of CBD directly to your lungs with every use.
Rxoid is manufactured using Current Good Manufacturing Practice (cGMP) that are mandated by the FDA with respect to the manufacture of all drugs and medical devices. This means we use the highest quality parts and manufacturing processes to ensure that Rxoid upholds a quality delivery system. It is important to do things to the proper standard in the CBD space and that is what we have set out to ensure.
Give our Rxoid MDI a try so that you can be confident in the fact that you are getting the natural and effective relief you deserve in every dose.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Rapid Therapeutic Science Laboratories current news coverage by the company. FNMG HOLDS NO SHARES OF Rapid Therapeutic Science Laboratories
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.